Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)

被引：21

作者：

Mercer, Swati P. ^{[1
]}

Roecker, Anthony J. ^{[1
]}

Garson, Susan ^{[2
]}

Reiss, Duane R. ^{[2
]}

Harrell, C. Meacham ^{[2
]}

Murphy, Kathy L. ^{[2
]}

Bruno, Joseph G. ^{[4
]}

Bednar, Rodney A. ^{[4
]}

Lemaire, Wei ^{[2
]}

Cui, Donghui ^{[3
]}

Cabalu, Tamara D. ^{[3
]}

Tang, Cuyue ^{[3
]}

Prueksaritanont, Thomayant ^{[3
]}

Hartman, George D. ^{[1
]}

Young, Steven D. ^{[1
]}

Winrow, Christopher J. ^{[2
]}

Renger, John J. ^{[2
]}

Coleman, Paul J. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA

[2] Merck Res Labs, Dept Neurosci, West Point, PA 19486 USA

[3] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA

[4] Merck Res Labs, West Point Facil Automat & Screening WP FAST, West Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 24期

关键词：

Orexin receptor antagonists; Selective orexin-2 receptor antagonists; Insomnia; Hypocretin; Rat sleep EEG; P-GLYCOPROTEIN; POTENT; SLEEP; PROMOTION;

D O I：

10.1016/j.bmcl.2013.10.045

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The orexin (or hypocretin) system has been identified as a novel target for the treatment of insomnia due to the wealth of biological and genetic data discovered over the past decade. Recently, clinical proof-of-concept was achieved for the treatment of primary insomnia using dual (OX1R/OX2R) orexin receptor antagonists. However, elucidation of the pharmacology associated with selective orexin-2 receptor antagonists (2-SORAs) has been hampered by the lack of orally bioavailable, highly selective small molecule probes. Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described. A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：6620 / 6624

页数：5

共 50 条

[41] (-)-Mefloquine as a starting point for the discovery of selective adenosine A2A receptor antagonists
Jordan, AM
Benwell, K
Cliffe, IA
Dourish, CT
Giles, PR
Gillespie, RJ
Knights, TR
Lerpiniere, L
Misra, A
Ward, SE
Weiss, SM
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2550 - U2551
[42] Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor
Oi, Norihito
Suzuki, Michiyuki
Terauchi, Taro
Tokunaga, Masaki
Nakatani, Yosuke
Ymamoto, Noboru
Fukumura, Toshimitsu
Zhang, Ming-Rong
Suhara, Tetsuya
Higuchi, Makoto
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 77P - 77P
[43] Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring
Iio, Keita
Saitoh, Tsuyoshi
Ohshita, Ryuichiro
Hino, Tsubasa
Amezawa, Mao
Takayama, Yoshiaki
Nagumo, Yasuyuki
Yamamoto, Naoshi
Kutsumura, Noriki
Irukayama-Tomobe, Yoko
Ishikawa, Yukiko
Tanimura, Ryuji
Yanagisawa, Masashi
Nagase, Hiroshi
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 60
[44] Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat
Dugovic, Christine
Shelton, Jonathan E.
Aluisio, Leah E.
Fraser, Ian C.
Jiang, Xiaohui
Sutton, Steven W.
Bonaventure, Pascal
Yun, Sujin
Li, Xiaorong
Lord, Brian
Dvorak, Curt A.
Carruthers, Nicholas I.
Lovenberg, Timothy W.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 330 (01): : 142 - 151
[45] A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
De Boer, Peter
Drevets, Wayne C.
Rofael, Hany
van der Ark, Peter
Kent, Justine M.
Kezic, Iva
Parapatics, Silvia
Dorffner, Georg
van Gerven, Joop
Benes, Heike
Keicher, Christian
Jahn, Holger
Seiden, David J.
Luthringer, Remy
JOURNAL OF PSYCHOPHARMACOLOGY, 2018, 32 (06) : 668 - 677
[46] Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice
Bonaventure, Pascal
Yun, Su Jin
Wennerholm, Michelle
Shelton, Jonathan
Letavic, Michael
Shireman, Brock
Lovenberg, Timothy
Dugovic, Christine
NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S421 - S421
[47] Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice
Yun, Sujin
Wennerholm, Michelle
Shelton, Jonathan E.
Bonaventure, Pascal
Letavic, Michael A.
Shireman, Brock T.
Lovenberg, Timothy W.
Dugovic, Christine
FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2017, 11
[48] Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats
Chang, Hyukki
Saito, Tsuyoshi
Ohiwa, Nao
Tateoka, Masaru
Deocaris, Custer C.
Fujikawa, Takahiko
Soya, Hideaki
NEUROSCIENCE RESEARCH, 2007, 57 (03) : 462 - 466
[49] Synthesis and evaluation of novel radioligands for positron emission tomography imaging of central orexin-2 receptor
Oi, Norihito
Suzuki, Michiyuki
Terauchi, Taro
Tokunaga, Masaki
Zhang, Ming-Rong
Suhara, Tetsuya
Higuchi, Makoto
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[50] Structure-activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands
Lang, MJ
Söll, RM
Dürrenberger, F
Dautzenberg, FM
Beck-Sickinger, AG
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (05) : 1153 - 1160

← 1 2 3 4 5 →